Grifols stabilises following challenging financial year
Spanish pharmaceutical and diagnostics group Grifols appears to be regaining stability after a turbulent financial year marked by investor uncertainty, public scrutiny, and significant restructuring. The company, based in Barcelona and best known for its leadership in plasma-derived medicines, experienced a series of challenges in 2024 that included a short-seller attack, questions over its accounting […]